Home › Compare › JBSAY vs ABBV
JBSAY yields 9.88% · ABBV yields 3.06%● Live data
📍 JBSAY pulled ahead of the other in Year 1
Combined, JBSAY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JBSAY + ABBV for your $10,000?
JBS S.A., a food company, processes and trades in animal protein worldwide. It offers beef, pork, chicken, and lamb products and by-products; food products; pet food and concentrates; and bresaola. The company also produces and commercializes steel cans, plastic resins, soap bases and bars, biodiesel, glycerin, fatty acid, collagen, and wrapper, as well as wet blue, semi-finished, and finished leather products; manages industrial residue; purchases and sells soybeans; and produces, cogenerates, and commercializes electric power. In addition, it is involved in tallow, palm oil, caustic soda, stearin, transportation, dog biscuits, hygiene and personal care, and sausage casings business; the operation of distribution centers and harbors; and the provision of cattle fattening, transportation, logistics, warehousing, and waste management and recycling services. Further, the company trades in cooked frozen meat; and operates Mercado da Carne store that provides beef and related items. It offers its products under the 1953, Doriana, Friboi, Massa Leve, Maturatta, Seara, Seara Gourmet, Swift, Angus Friboi, Anglo, Big Frango, Bordon, Confiança, delicate, Do Chef, Frangosul, Frigor Hans, LeBon, Reserva Friboi, Rezende, 1855, Incrível Seara, 5 Star, Aspen Ridge, Plumrose, Gold'n Plump, Just Bared Chicken, La Herencia, Moy Park, Pilgrim's, Primo, Rigamonti, and Swift Black. The company was formerly known as Friboi Ltda. JBS S.A. was founded in 1953 and is headquartered in São Paulo, Brazil.
Full JBSAY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.